Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Document › Details

GlaxoSmithKline plc. (3/1/17). "Press Release: GSK Confirms Closure of Agreement to Divest Anaesthesia Portfolio to Aspen". London.

Region Region ww excl North America
Organisations Organisation GlaxoSmithKline plc (LSE: GSK, NYSE: GSK)
  Today GSK plc (LSE: GSK, NYSE: GSK)
  Group GSK (Group)
  Organisation 2 Aspen Pharmacare Holdings Ltd.
Product Product Ultiva®

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the closure of an agreement with Aspen (JSE: APN) aligned with GSK’s strategy of simplification through focusing on core therapeutic areas.

GSK has divested its anaesthesia portfolio to Aspen (excluding the US and Canada which had been previously divested) for £180m plus milestones of up to £100m.

Notes to editors:

> GSK’s anaesthesia portfolio consists of Ultiva, Nimbex, Tracrium, Mivacron and Anectine.

> GSK 2016 full year sales of the anaesthesia portfolio were approximately £70 million.

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit

GSK enquiries:

UK Media enquiries:

Simon Steel
+44 (0) 20 8047 5502
Anna Carruth
+44 (0) 20 8047 5502

US Media enquiries:

Sarah Alspach
+1 202 715 1048
(Washington, DC)
Sarah Spencer
+1 215 751 3335

Analyst/Investor enquiries:

Tom Curry
+ 1 215 751 5419
Gary Davies
+44 (0) 20 8047 5503
James Dodwell
+44 (0) 20 8047 2406
Jeff McLaughlin
+1 215 751 7002

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2015.

Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex

Record changed: 2023-06-05


Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x200px

More documents for GSK (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x300px

» top